INO
Income statement / Annual
Last year (2025), Inovio Pharmaceuticals Inc's total revenue was $65.34 K,
a decrease of 69.99% from the previous year.
In 2025, Inovio Pharmaceuticals Inc's net income was -$84.95 M.
See Inovio Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$65.34 K |
$217.76 K |
$832.01 K |
$10.26 M |
$1.77 M |
$7.41 M |
$4.11 M |
$30.48 M |
$42.22 M |
$35.37 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$65.34 K
|
$217.76 K
|
$832.01 K
|
$10.26 M
|
$1.77 M
|
$7.41 M
|
$4.11 M
|
$30.48 M
|
$42.22 M
|
$35.37 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$54.21 M
|
$75.62 M
|
$86.68 M
|
$187.65 M
|
$249.24 M
|
$94.25 M
|
$88.02 M
|
$95.26 M
|
$98.57 M
|
$88.71 M
|
| General & Administrative Expenses |
$32.68 M
|
$37.00 M
|
$47.58 M
|
$90.19 M
|
$53.75 M
|
$37.25 M
|
$27.20 M
|
$29.32 M
|
$28.29 M
|
$23.89 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$32.68 M
|
$37.00 M
|
$47.58 M
|
$90.19 M
|
$53.75 M
|
$37.25 M
|
$27.20 M
|
$29.32 M
|
$28.29 M
|
$23.89 M
|
| Other Expenses |
$0.00
|
$0.00
|
$10.51 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$360.80 K
|
$806.82 K
|
$127.55 K
|
| Operating Expenses |
$86.89 M
|
$112.62 M
|
$144.77 M
|
$277.84 M
|
$302.99 M
|
$131.49 M
|
$115.22 M
|
$124.57 M
|
$126.86 M
|
$112.60 M
|
| Cost And Expenses |
$86.89 M
|
$112.62 M
|
$144.77 M
|
$277.84 M
|
$302.99 M
|
$131.49 M
|
$115.22 M
|
$124.57 M
|
$126.86 M
|
$112.60 M
|
| Interest Income |
$2.42 M
|
$4.77 M
|
$8.13 M
|
$4.78 M
|
$3.36 M
|
$3.31 M
|
$2.61 M
|
$2.26 M
|
$1.84 M
|
$1.40 M
|
| Interest Expense |
$0.00
|
$177.83 K
|
$1.22 M
|
$1.25 M
|
$1.94 M
|
$8.70 M
|
$7.95 M
|
$0.00
|
$25.93 K
|
$139.25 K
|
| Depreciation & Amortization |
$2.99 M
|
$3.13 M
|
$3.50 M
|
$5.50 M
|
$4.73 M
|
$4.63 M
|
$5.52 M
|
$5.00 M
|
$3.47 M
|
$3.09 M
|
| EBITDA |
-$81.96 M |
-$103.95 M |
-$130.39 M |
-$270.90 M |
-$296.56 M |
-$149.56 M |
-$107.34 M |
-$89.80 M |
-$84.74 M |
-$74.15 M |
| EBITDA Ratio |
-1254.26
|
-477.35
|
-156.72
|
-26.4
|
-167.1
|
-20.18
|
-26.11
|
-2.95
|
-2.01
|
-2.1
|
| Operating Income Ratio |
-1328.71
|
-516.17
|
-173
|
-26.07
|
-169.72
|
-16.74
|
-27.02
|
-3.09
|
-1.98
|
-2.16
|
| Total Other Income/Expenses Net |
$1.88 M
|
$5.14 M
|
$8.82 M
|
-$12.24 M
|
-$2.44 M
|
-$43.39 M
|
-$9.70 M
|
-$706.88 K
|
-$4.56 M
|
$2.50 M
|
| Income Before Tax |
-$84.95 M
|
-$107.25 M
|
-$135.12 M
|
-$279.82 M
|
-$303.66 M
|
-$167.47 M
|
-$120.81 M
|
-$94.80 M
|
-$88.21 M
|
-$73.74 M
|
| Income Before Tax Ratio |
-1300
|
-492.54
|
-162.4
|
-27.27
|
-171.1
|
-22.6
|
-29.38
|
-3.11
|
-2.09
|
-2.08
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$257.34 K
|
$2.17 M
|
$0.00
|
$0.00
|
| Net Income |
-$84.95 M
|
-$107.25 M
|
-$135.12 M
|
-$279.82 M
|
-$303.66 M
|
-$166.41 M
|
-$119.36 M
|
-$96.97 M
|
-$88.21 M
|
-$73.74 M
|
| Net Income Ratio |
-1300
|
-492.54
|
-162.4
|
-27.27
|
-171.1
|
-22.45
|
-29.03
|
-3.18
|
-2.09
|
-2.08
|
| EPS |
-1.81 |
-3.95 |
-6.09 |
-14.07 |
-1.42 |
-1.07 |
-0.97 |
-1.05 |
-1.08 |
-1.01 |
| EPS Diluted |
-1.81 |
-3.95 |
-6.09 |
-14.07 |
-1.42 |
-1.07 |
-0.97 |
-1.05 |
-1.08 |
-1.01 |
| Weighted Average Shares Out |
$468.86 M
|
$27.16 M
|
$22.17 M
|
$19.89 M
|
$214.62 M
|
$165.36 M
|
$124.62 M
|
$92.35 M
|
$81.78 M
|
$73.01 M
|
| Weighted Average Shares Out Diluted |
$468.86 M
|
$27.16 M
|
$22.17 M
|
$19.89 M
|
$214.62 M
|
$169.87 M
|
$124.62 M
|
$92.54 M
|
$81.92 M
|
$73.21 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
